Distribution of PIM-1, PAX-5, RhoH/TTF, c-MYC, and BCL-6 mutations throughout the clinicopathologic spectrum of AIDS-NHL
. | Mutated/tested (%) . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | c-MYC . | c-MYC . | . | |||||
| Histology . | PIM-1 . | PAX-5 . | RhoH/TTF . | exon 1 . | exon 2 . | BCL-6 . | |||||
| AIDS-NHL (all) | 5/39 (12.8) | 8/39 (20.5) | 9/39 (23.1) | 3/27 (11.1) | 4/27 (14.8) | 24/39 (61.5) | |||||
| Systemic AIDS-NHL | |||||||||||
| Burkitt lymphoma | 1/11 (9.1) | 3/11 (27.3) | 2/11 (18.2) | NA | NA | 5/11 (45.4) | |||||
| Diffuse large B-cell lymphoma | 4/18 (22.2) | 4/18 (22.2) | 4/18 (22.2) | 2/17 (11.8) | 3/17 (17.6) | 11/18 (61.1) | |||||
| AIDS-PCNSL | 0/4 | 0/4 | 1/4 (25) | 0/4 | 1/4 (25) | 3/4 (75) | |||||
| AIDS-PEL | 0/6 | 1/6 (16.7) | 2/6 (33.3) | 1/6 (16.7) | 0/6 | 5/6 (83.3) | |||||
. | Mutated/tested (%) . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | c-MYC . | c-MYC . | . | |||||
| Histology . | PIM-1 . | PAX-5 . | RhoH/TTF . | exon 1 . | exon 2 . | BCL-6 . | |||||
| AIDS-NHL (all) | 5/39 (12.8) | 8/39 (20.5) | 9/39 (23.1) | 3/27 (11.1) | 4/27 (14.8) | 24/39 (61.5) | |||||
| Systemic AIDS-NHL | |||||||||||
| Burkitt lymphoma | 1/11 (9.1) | 3/11 (27.3) | 2/11 (18.2) | NA | NA | 5/11 (45.4) | |||||
| Diffuse large B-cell lymphoma | 4/18 (22.2) | 4/18 (22.2) | 4/18 (22.2) | 2/17 (11.8) | 3/17 (17.6) | 11/18 (61.1) | |||||
| AIDS-PCNSL | 0/4 | 0/4 | 1/4 (25) | 0/4 | 1/4 (25) | 3/4 (75) | |||||
| AIDS-PEL | 0/6 | 1/6 (16.7) | 2/6 (33.3) | 1/6 (16.7) | 0/6 | 5/6 (83.3) | |||||
NA indicates not applicable; in these cases mutations of c-MYC were not considered because of the presence of gross rearrangements of the gene to the immunoglobulin loci.